Investor Area

Home / Investor Area / News / SCENESSE® presented at ICPP in Milan
 

SCENESSE® presented at ICPP in Milan

 

CLINUVEL PHARMACEUTICALS LTD today announced that safety and effectiveness data from the treatment of erythropoietic protoporphyria (EPP) patients with SCENESSE® (afamelanotide 16mg), will be presented this week at the International Congress on Porphyrins and Porphyrias (ICPP) in Milan, Italy. […]

Download PDF